CASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report

Similar documents
Paroxysmal Nocturnal Hemoglobinuria

What is PNH? PNH: What it is Not 9/11/2015. What is Paroxysmal Nocturnal Hemoglobinuria?

Pathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Congenital dyserythropoietic anaemia type II-like dysplastic anaemia preceding the development of non-hodgkin lymphoma a case report.

Living with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease

The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria

PNH. PNH A study case 5/9/2012. PNH Current Thinking on the Disease, Diagnosis, and Treatment. Where have we been, where are we going?

PNH. What is PNH? 7/12/2016 PNH. What is PNH? 1 st published case report of PNH

PNH Glossary of Terms

PNH PNH PNH 3/22/2016 PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH): Current Thinking on the Disease PATHOGENESIS OF PNH

Dana Alsulaibi. - Ahmad Almuhtaseb. - Tariq Al - Adaily

Aplastic Anemia Pathophysiology and Approach to Therapy

9/19/2017. PNH Understanding your diagnosis and treatment. Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria

Key terms: aplastic anemia; complement inhibitors; paroxysmal nocturnal hemoglobinuria

PNH: Current Thinking on the Disease, Diagnosis and Treatment. What is PNH? 7/6/2009. Paroxysmal sudden onset Nocturnal

Year 2002 Paper two: Questions supplied by Jo 1

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018

International Journal of Case Reports in Medicine

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine

eculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd

Clinical Roundtable Monograph

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial

Immunohematology (Introduction)

Leukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College

10/27/2017 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DANIEL LANDAU, MD PNH TYPICAL CASE

Improved prognosis for acquired aplastic anaemia

SESSION 1 Reactive cytopenia and dysplasia

CASE SERIES Juvenile myelomonocytic leukaemia: a case series

Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration

Non-immune acquired haemolytic anaemias. Dr.Maysem

All you wanted to know about transfusion support for transplants

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed

PAROXYSMAL nocturnal hemoglobinuria (PNH) is

Passenger Lymphocyte Syndrome (case presentation) Dr. Namal Bandara Kings College Hospital

Paroxysmal Nocturnal Hemoglobinuria

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Immunohematology (Introduction) References: -Blood Groups and Red Cell Antigens (Laura Dean) -Cellular and molecular immunology, 8 th edition

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD

How to diagnose myeloproliferative neoplasms and PNH in vascular diseases of the liver Valerio De Stefano

SOLIRIS (eculizumab) Slide # 1. How do we treat PNH?

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

XIV. HLA AND TRANSPLANTATION MEDICINE

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Slide # 1. What is PNH and what is the long term outlook? Carlos M. de Castro, MD Duke University Medical Center. October 2012 AA&MDSIF Conference

C. treatment with Desferal (deferoxamine mesylate USP, iron-chelating agent)

New Phase III Clinical Trial Enrolling Now

Anemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib

CASE REPORT Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh

What is meant by Thrombotic Microangiopathy (TMA)?

Case Report A Case of WarmAutoimmune HaemolyticAnaemiaPresenting with Intravascular Haemolysis

Evaluation of two types of leukocyte removal filters on transfusion dependent thalassaemics

Dr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report

CASE REPORT A family study of HbS in a Malay family by molecular analysis

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies

New Insights into Paroxysmal Nocturnal Hemoglobinuria

Customer Information Literature List Platelets

Things to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC

Should we still use Camitta s criteria for severe aplastic anemia?

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology

Management Issues in Paroxysmal Nocturnal Hemoglobinuria. Gabrielle Meyers, M. D. and Charles J. Parker, M. D.

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

Early View Article: Online published version of an accepted article before publication in the final form.

4/17/2018. Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria. Epidemiology. PNH Stem Cell.

WHAT IS YOUR DIAGNOSIS?

YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY

Rory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital

Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored proteindeficient

Specific Requirements

Domenico Bianco, DVM, PhD, DACVIM August, 26 th 2013

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology

CASE REPORT Double Philadelphia chromosome-positive B acute lymphoblastic leukaemia in an elderly patient

Cynthia Fata, MD, MSPH 6/23/15

Contents SECTION 1: PHYSIOLOGY OF BLOOD

prediction of severe neonatal hyperbilirubinaemia

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options

HEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Lay Summaries ASH 2017

Haemolytic anaemias. Dr. J Potgieter Department of Haematology NHLS Tshwane Academic Division

ERROR CORRECTION FORM

Supplementary Appendix

Slide # 1. PNH: Comlications and. Long-Term Issues. Long-Term Issues. What is PNH and what is the long term outlook?

HAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore

Glucose-6-P-dehydrogenase deficiency. Béatrice GULBIS, M.D., PhD

Immune Mediated Haemolytic Anaemia Secondary to Sheathed Microfilaria A Case Report

Blood Product Modifications: Leukofiltration, Irradiation and Washing

ALXN 1210 for paroxysmal nocturnal haemoglobinuria first line

Transplantation. Immunology Unit College of Medicine King Saud University

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Dairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009

Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF

Examination Tests from Pathological Physiology. Pavel Maruna et al. Reviewed by: Prof. MUDr. Emanuel Nečas, DrSc. Prof. MUDr. Jaroslav Veselý, CSc.

Junfeng Wang 12/10/2010

Transcription:

Malaysian J Pathol 2006; 28(2) : 107 112 CASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report R Z Azma, MBBS, MPATH, N H Hamidah, MBBCh, Dr Med Sc, C-F Leong, MPATH, FRCPA, O Ainoon, MBBS, Dr Med Sc, S-K Cheong, FRCP, FRCPA Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Abstract Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired haemopoietic stem cell disorder arising from somatic mutation of the X-linked PIG-A gene which leads to deficiency of the glycosylphosphatidylinositol (GP1) membrane anchor proteins such as CD 59 (MIRL: membrane inhibitor of reactive lysis) and CD 55 (DAF: decay accelerating factor). Allogeneic peripheral blood stem cell transplant (PBSCT) is a curative mode of treatment in symptomatic PNH patients. Assessment of donor chimerism for PBSCT can be performed by various methods including short tandem repeat loci (STR) and variable number of tandem repeats (VNTR). Flow cytometry, which is much cheaper and faster, also can be used to assess engraftment in patients with PNH. Engrafted patients will show the presence of CD 55 and CD 59 on their red cells and white cells. We describe here the usefulness of flow cytometry in the assessment of donor chimerism following allogeneic PBSCT, in a case of PNH. Key words: Flow cytometry, allogeneic peripheral blood stem cell transplant, donor chimerism. INTRODUCTION Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disorder of insidious onset, characterized by attacks of intravascular haemolysis and early morning haemoglobinuria. It is an acquired anaemia caused by complement-mediated haemolysis. It arises as a result of somatic mutation of the X-linked PIG-A gene that affects the synthesis of the glycosylphosphatidylinositol (GP1) membrane anchor required for several membrane proteins such as CD 59 (MIRL: membrane inhibitor of reactive lysis) and CD 55 (DAF: decay accelerating factor). The mutation arises in an abnormal clone of haemopoietic stem cells and affects GPI anchored molecules on all haemopoietic lineages. Patients with PNH have abnormal red blood cells that are sensitive to complement due to the deficiency of cell surface complement regulatory proteins CD59 and CD55. 1 The absence of these proteins is the most reliable diagnostic criterion of the disease and is responsible for many of the clinical manifestations of PNH. GPI-anchor proteins are also missing from white cells and platelets. There is a close association with aplastic anaemia (AA) and patients may present with a disease having characteristics of both AA and PNH. 2 The thrombophilia of PNH is characterized by venous thrombosis occurring at unusual sites such as cerebral or mesenteric veins. The diagnosis of PNH using immunophenotyping is more sensitive and specific even after blood transfusion. After stem cell transplantation, donor chimerism can also be assessed using flow cytometry. Case report A 34-year-old Chinese man presented with severe anaemia for one year. He also had history of haemoglobinuria early in the morning. He was admitted to a private hospital and required multiple blood transfusions. He had a splenectomy but his anaemia did not improve and he was referred to UKM Hospital for further management. On admission, he was very pale and jaundiced. There was a splenectomy scar. His full blood counts at admission showed that Address for correspondence and reprint requests: Dr. Raja Zahratul Azma bt. Raja Sabudin, Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia. Fax: 603-91737340, Tel no: 603-91733333 ext 5780/2254. E-mail: zahratul@mail.hukm.ukm.my 107

Malaysian J Pathol December 2006 T F N P H FIG. 1: Peripheral blood film (Wright stain x 40) showing polychromatic cells (P), nucleated red cells (N), target cells (T), Howell-jolly body (H) and fragmented red cells (F) he was anaemic with high reticulocytosis. His haemoglobin level was 7.7g/dl, the platelet count was 221 x 10 9 /l and the total white cells count was 10.8 x 10 9 /l. The reticulocyte count was 14.4%. The full blood picture (Figure 1) showed anisopoikilocytosis with polychromasia. There was spherocytosis with microspherocytes seen. Numerous target cells were noted. There were numerous nucleated red cells with a few Howell Jolly bodies seen. The platelet count was more than 193 x 10 9 /l with many giant platelets seen. Most neutrophils were hypersegmented. The white cell differential count was: neutrophils 36%, lymphocytes 28%, nucleated red cells 22%, monocytes 14%. Renal profile was normal (sodium 139 mmol/l, potassium 4.0 mmol/l, urea 3.7 mmol/l, creatinine 74 µmol/l). Random blood sugar was normal (4.8 mmol/l). His liver function test was abnormal; he had high bilirubin however other parameters were within normal limits (total protein 82 g/l, albumin 48 g/l, total bilirubin 61 µmol/l, alkaline phosphatase 57 U/L, alanine transaminase 14 U/L). G6PD screening was normal. Direct and indirect Coombs tests were negative. Urine hemosiderin was positive. Ham s test showed lysis in acidified serum. Immunophenotyping showed that the population of red cells and granulocytes were negative for CD 55 and CD 59 (Figures 2 and 3). He was diagnosed to have paroxysmal nocturnal haemoglobinuria. Warfarin was started but was later changed to aspirin as he developed allergic reactions towards the drug. A nonmyeloablative allogeneic PBSCT was performed for him and the donor was his brother. On the 18 th day post transplantation, he developed an urticaria rash. On the same day peripheral blood sample for short tandem repeat loci (STR) was done and the results showed that full chimerism was achieved (Figure 4). One-month post transplant, repeated urine haemosiderin was negative. Ham s test showed no lysis in acidified serum. Serum bilirubin level was normalized (Figure 5). Bone marrow aspiration sent for immunophenotyping showed that both red cells and granulocytes were positive for CD55 and CD 59. His haemoglobin level was normalized. STR was done and the results showed that full chimerism was achieved (Figure 4). On day 36 post transplantation he developed more erythematous rashes over the inner thighs, trunk and shoulders. At the same time his liver enzymes started to rise. The ALT and ALP were 59 U/L and 152 U/L respectively. His cyclosporin dosage was increased to 125mg bd. In view of the acute GVHD, prednisolone was later added while on cyclosporin to control the GVHD. 108

FLOW CYTOMETRY FOR DONOR CHIMERISM (a) (b) FIG. 2: Immunophenotyping for CD55 and CD59 in patient s red cells: (a) Before PBSCT: Flow cytometry showed negative expression of both proteins on patient s red cells. However, some population of red cells had positive expression for CD59 and CD55 (most likely contaminated with transfused red cells). (b) After PBSCT:both CD55 and CD59 are expressed on patient s red cells, indicating complete donor chimerism, control red cells were from the donor. DISCUSSION Paroxysmal nocturnal haemoglobinuria is an acquired disorder of the red cell membrane. There are two proteins, DAF (CD55), which accelerates the conversion of C3b to the inactive C3d and MIRL (CD59), which protects the cell from lysis by the membrane attack complex (MAC), that are attached to the membrane by the GPI-anchor. Absence of these proteins leads to an increase in susceptibility to complement lysis by several folds. GPI-anchor proteins are also missing from white cells and platelets, and the lack of CD59 on platelets may account for the thrombotic tendency in patients with PNH. 3 The diagnosis of PNH in this patient was confirmed after full blood investigations were done at Hospital UKM. The Ham s test showed lysis in acidified serum and his immunophenotyping analysis showed a population of red cells and granulocytes, which were negative for CD 55 and CD 59. The flow cytometric assay is more sensitive and more specific than the Ham s or sucrose lysis tests, and is particularly helpful for diagnosis in the early stage of the disease, when only a small part of the total blood cell population may be affected. It allows estimating the proportions of PNH type I, II and III erythrocytes reflecting changes in the proportion of abnormal hematopoietic bone marrow cells. In our patient (Figure 2), it showed two populations of cells: normal (type I) and partial deficiency (type II) of CD59 expression, and those PNH type II cells were no longer present following transplantation. However, 109

Malaysian J Pathol December 2006 (a) (b) FIG. 3: Immunophenotyping for CD55 and CD59 in the patient s white cells: (a) Before PBSCT: Flow cytometry showed negative expression of both proteins on the patient s white cells. (b) After PBSCT: Both CD55 and CD59 were expressed on the patient s white cells, indicating complex donor chimerism, control granulocytes were from the donor. the patient had received multiple packed cells transfusions before transplantation, thus the normal red cells were actually from the transfused blood. The white cells showed only PNH type II cells (partially deficient of CD55) and those cells were also absent following transplantation (Figure 3). This patient was having symptomatic chronic haemolytic anaemia and required regular blood transfusion. In PNH, the treatment is directed either at the symptoms that arise as a result of the defective cells or at the hematopoietic defect. As we have seen in this patient, he received multiple blood transfusions due to severe anaemia. He also had splenectomy done before he was admitted to HUKM; however the operation was not helpful in controlling the haemolysis. Immunosuppression with antithymocyte globulin (ATG) may induce a remission in bone marrow depression in some patients with PNH. Studies by Paquette et al, showed that ATG was able to improve peripheral blood cytopenias in patients with a hypoproliferative form of PNH 4 but not in haemolytic PNH. Bone marrow transplantation remains an effective alternative for symptomatic patients. With the availability of suitable donors, allogeneic stem cells transplantation (SCT) is the only curative treatment for PNH. The haemoglobin level in our patient improved after PBSCT (Figure 6) and he did not require any more blood transfusion. His bilirubin level was also normalized (Figure 5) indicating that there was no more underlying haemolysis of red cells. Flow cytometry (Figures 2 & 3), which 110

FLOW CYTOMETRY FOR DONOR CHIMERISM Patient s alleles, before transplant Donor s alleles, before transplant Patient s allele, after transplant FIG. 4: Short tandem repeat loci done at 1 month post PBSCT showed complete donor chimerism. was done at 18 days after PBSCT showed CD55 and CD59 were positive for both red cells and granulocytes. The median survival of patients with PNH is 10 15 years. Without SCT, since it is not a malignant condition, spontaneous remission can occur in about 15% of patients. 5 Donor chimerism can be assessed by many methods. In early studies, red cell antigens were used to demonstrate the presence of donor cells after PBSCT such as ABO, Rhesus, MNSs, Duffy, Kidd or Kell. However, this method only can be done if both donor and recipient have different red cell antigens and assay results can be confounded by red cell transfusions before and after PBSCT. Other methods such as erythrocyte enzymes also can be used for analyses of chimerism after 20/11/2002 27/11/2002 4/12/2002 11/12/2002 18/12/2002 25/12/2002 1/1/2003 8/1/2003 15/1/2003 22/1/2003 29/1/2003 5/2/2003 12/2/2003 19/2/2003 26/2/2003 5/3/2003 12/3/2003 FIG. 5: Bilirubin levels of the patient before and after PBSCT ( ) 111

Malaysian J Pathol December 2006 FIG. 6: Haemoglobin levels of the patient before and after PBSCT ( ). PBSCT by looking at enzyme polymorphisms identified as electrophoretic mobility variants. However it also suffers the same problems as erythrocyte antigens. HLA antigens also can be used as informative genetic markers only when there is HLA disparity between the donor and recipient. Conventional cytogenetics can be done if there is gender disparity between the donor and recipient. However methods such as short tandem repeat loci or variable number tandem repeat polymorphisms using DNA amplification are the most sensitive and specific methods. There are varieties of allele present in a population, so a high degree of discrimination among individuals in the population may be obtained when multiple STR loci are examined. Thus, even when donor and recipient are of the same sex, same HLA types or blood group antigens, by using multiple STR loci examination, the presence of donor haematopoietic cells can be assessed accurately. Unfortunately, the molecular methods are very expensive. As illustrated by this case, immunophenotyping can be used to assess chimerism. The recipient red cells and granulocytes are negative for CD 55 and CD 59. If donor chimerism occurs, population of red cells and granulocytes with positive CD 55 and CD 59 can be seen. The tests are much cheaper and the patient can be assessed more frequently. Besides, the chimerism status can be quantified. If the patient has recurrent red cell transfusion, assessment still can be done by using granulocytes instead of red cells. REFERENCES 1. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal haemoglobinuria. Blood 1995; 86: 3277-86. 2. Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone marrow hypoplasia. Br J Haematol 1961; 7, 442 57. 3. Rosse WF. New insights into paroxysmal nocturnal haemoglobinuria. Curr Opin Hematol 2001; 8:61-7. 4. Paquette RL, Yoshimura R, Veiseh C, et al. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1997; 96, 92-7. 5. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal haemoglobinuria. N Engl J Med 1995; 333, 1253-8. 112